CeriBell (NASDAQ:CBLL) Hits New 1-Year High Following Analyst Upgrade

CeriBell (NASDAQ:CBLL)’s share price reached a new 52-week high on Monday after TD Cowen raised their price target on the stock from $31.00 to $36.00. TD Cowen currently has a buy rating on the stock. CeriBell traded as high as $31.82 and last traded at $31.82, with a volume of 9376 shares. The stock had previously closed at $30.24.

Other analysts have also issued research reports about the company. JPMorgan Chase & Co. began coverage on CeriBell in a report on Tuesday, November 5th. They set an “overweight” rating and a $32.00 target price for the company. Canaccord Genuity Group upped their target price on CeriBell from $31.00 to $33.00 and gave the stock a “buy” rating in a report on Monday. Canaccord Genuity Group started coverage on CeriBell in a report on Tuesday, November 5th. They set a “buy” rating and a $30.00 price objective for the company. Bank of America started coverage on CeriBell in a report on Tuesday, November 5th. They set a “buy” rating and a $32.00 price objective for the company. Finally, William Blair started coverage on CeriBell in a report on Tuesday, November 5th. They set an “outperform” rating for the company. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $32.60.

CeriBell Price Performance

CeriBell (NASDAQ:CBLL) last released its earnings results on Tuesday, November 12th. The company reported ($1.85) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by ($1.03). The business had revenue of $17.20 million for the quarter, compared to analyst estimates of $17.06 million. Equities research analysts anticipate that CeriBell will post -2.46 earnings per share for the current fiscal year.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.